Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Video

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Related Videos
A man with a dark gray button-up shirt with glasses and cropped brown hair.
MPN Hero, Ed Bartholemy in an interview with CURE
Julie Huynh-Lu in an interview with CURE
Myelofibrosis Panel
Dr. John O. Mascarenhas
Related Content
Image of blood cells moving together.

Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis

April 16th 2024
Article

Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.

Read More

Cancer Horizons podcast logo

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

January 8th 2024
Podcast

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

Listen

Image of a doctor wearing a blue rubber glove, holding a vial of blood next to a rack of seven other vials.

New Drug May Decrease Need for Blood Draws in Patients With PV

February 23rd 2024
Article

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

Read More

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

December 16th 2021
Podcast

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

Listen

video image

Community Helped a Patient When Their MPN Treatment Was Delayed

December 29th 2023
Article

Thomas Silver discusses how a community of support helped a patient when his bone marrow transplant was delayed.

Read More

mpn image

What is Cytoreduction in MPNs?

December 25th 2023
Article

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

Read More